Dr Luke on the Background of the KEYNOTE-716 Trial in High-Risk Melanoma
August 18th 2023Jason Luke, MD, FACP, discusses the background of the phase 3 KEYNOTE-716 trial of pembrolizumab vs placebo as adjuvant therapy in patients with stage IIB or IIC melanoma, highlighting previous data from the trial that led to the 36-month follow-up report.
Read More
Practical Advice on the Evolving Management of CSCC
Closing out their discussion on the management of cutaneous squamous cell carcinoma, expert panelists share clinical pearls and excitement for the future.
Read More
CSCC: Escalating Therapy for High-risk Patients
Dr Vishal Patel shares a surgeon’s perspective on MDC, followed by a discussion on how intensifying treatment after surgery may improve outcomes for higher-risk patients with CSCC.
Read More
Best Practices in Multidisciplinary Care for CSCC
Experts in the field of CSCC revisit the concept of multidisciplinary care and consider best communication strategies.
Read More
Other Emerging Treatment Modalities in Cutaneous Squamous Cell Carcinoma
Shared insight on novel treatment modalities in the setting of cutaneous squamous cell carcinoma and how they may be triaged moving forward.
Read More
CSCC: Translating Cemiplimab Data Into Practice
Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.
Read More
Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates
A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.
Read More
Lessons Learned in Other Cancers and Suggested Endpoints in Future Trials
Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.
Read More
Clinical Experience With Neoadjuvant IO Therapy in Melanoma
Shared insight on the use of immune checkpoint inhibitors in other patient populations within the skin cancer paradigm, and how lessons may be applied to patients with CSCC.
Read More
Evolving Treatment Paradigm of Resectable CSCC
Expert panelists consider the broader evolution of therapy in resectable stage II-IV cutaneous squamous cell carcinoma.
Read More
Real World Experience With Resectable Cutaneous Squamous Cell Carcinoma
Expert perspectives on real-world, in-practice identification and management of patients with resectable CSCC.
Read More
Staging and Risk Stratification’s Impact on Treatment Approach in CSCC
Panelists round out their review of staging and risk stratification in CSCC by considering how each affects the selection of optimal surgical strategies.
Read More
Defining Resectability in CSCC
Following their discussions on staging and risk stratification in CSCC, key opinion leaders work to define resectability in cutaneous squamous cell carcinoma.
Read More
Optimal Risk Stratification in Patients With Cutaneous Squamous Cell Carcinoma
Expert panelists share their perspectives on best strategies to risk stratify patients diagnosed with cutaneous squamous cell carcinoma.
Read More
Available Staging Systems for Cutaneous Squamous Cell Carcinoma
A review of current staging systems used to categorize CSCC, particularly those from the American Joint Committee on Cancer and Brigham and Women's Hospital.
Read More
Cutaneous Squamous Cell Carcinoma: Incidence and Risk Factors
Opening their discussion on resectable cutaneous squamous cell carcinoma (CSCC), expert panelists elucidate its current incidence and known risk factors.
Read More
Treatment Optimization for Patients With Melanoma
Read More
Future Treatment Landscape for Melanoma
Read More
Promising Late-Stage Trials in Melanoma
Read More
Targeted Therapy Versus IO for Relapsed/Refractory Melanoma
Read More
Novel Approaches for Relapsed/Refractory Melanoma
Read More
Management of Brain Metastases in Melanoma
Read More
I/O Dosing Schedules in Metastatic Melanoma
Read More
Novel Therapies for Metastatic Melanoma
Read More
Systemic Therapy for Metastatic Melanoma
Read More
Adjuvant Therapy for Melanoma: Safety and Efficacy
Read More
Adjuvant Therapy for Melanoma: Ongoing Studies of Interest
Read More
Adjuvant Data Explored for Locally Advanced Melanoma
Read More
Neoadjuvant Data Explored for Locally Advanced Melanoma
Read More
pCR and Neoadjuvant Therapy for Melanoma
Read More